Assistant Professor of Medicine, Massachusetts General Hospital
Hematology
Dr. Bimalangshu R. Dey, MD
|
|
Give Review
Bimalangshu is an expert in the field of Hematology. He over the years received 1 awards: "Meaningful Use Stage 1 Certification". Doctor Bimalangshu R. Dey, MD has written publications. He has 59 publications published with PubMed. The lastest publication is: 'Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.' Doctor Bimalangshu R. Dey, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- Phase II Trial of Reduced Intensity Busulfan / Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL.
- Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem Cell transplantation.
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloi...
- Engraftment Syndrome after allogeneic hematopoietic cell transplantation in adults.
- Phase I Study of Urate Oxidase in the Reduction of Acute Graft-vs-Host Disease Following Myeloablative Allogeneic Stem Cell Transplantation.
- Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.
- Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem Cell transplantation for hematologic malignancies.
- Risk factors for invasive fungal Disease after allogeneic hematopoietic stem cell transplantation: a single center experience.
- Chronic graft-versus-host disease with skin signs suspicious for squamous cell carcinoma.
- Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients.
- Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia.
- Multicenter study of banked third party virus-specific T-Cells to treat severe viral infections after hematopoietic stem Cell transplantation.
- Expression of ñ4ò7 integrin on memory CD8(+) T cells at the presentation of Acute intestinal GVHD.
- The expanding frontier of hematopoietic Cell transplantation.
- Phase II Trial of Parathyroid Hormone following Double Umbilical Cord Blood Transplantation.
- Selection of optimal alternative Graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant.
- High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin Lymphoma.
- Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal Disease.
- Cardiac transplantation followed by dose-intensive melphalan and autologous stem-Cell transplantation for light chain amyloidosis and heart failure.
- Control of plasma uric acid in adults at risk for tumor Lysis Syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared wit...
- Donor-derived second hematologic malignancies after cord blood transplantation.
- von Willebrand Disease type 2N: uncovering a congenital bleeding disorder in a patient with hepatitis C, cirrhosis, and coagulopathy.
- Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma: a single-institution exp...
- Case records of the Massachusetts General Hospital. Case 28-2009. A 68-year-old man with fatigue, cough, and Peripheral-blood monocytosis.
- High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults.
- Phase I trial of parathyroid hormone to facilitate stem Cell mobilization.
- Double unrelated reduced-intensity umbilical cord blood transplantation in adults.
- Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-2004. A 58-year-old man with Acute myeloid leukemia and Fever after c...
- Nonmyeloablative haploidentical stem-Cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies.
- Impact of prophylactic donor leukocyte infusions on mixed chimerism, Graft-versus-host disease, and antitumor response in patients with advanced hematologic malignanci...
- Lineage switch of Acute lymphocyctic leukaemia with t(4;11)(q21;q23) into Acute myeloid leukaemia in an adult patient after allogeneic stem cell transplantation.
- Current status of haploidentical stem Cell transplantation.
- Regulatory T-Cell recovery in recipients of haploidentical nonmyeloablative hematopoietic Cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without...
- Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem Cell transplantation.
- Cellular Immune therapy for refractory cancers: novel therapeutic strategies.
- Role of Interferon-gamma in GVHD and GVL.
- Interleukin-12 prevents severe Acute graft-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mism...
- The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a Graft-versus-host disease model.
- Successful allogeneic stem Cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem Cell tran...
- Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin''s Lymphoma.
- Induction of kidney alloGraft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease.
- Interleukin-12 inhibits Graft-versus-host disease through an Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion.
- Outcomes of recipients of both bone marrow and solid organ transplants. A review.
- Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants.
- Clinical outcomes of late rather than early full-donor chimerism in patients with advanced Lymphomas receiving nonmyeloablative allogeneic hematopoietic SCT.
- Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses.
- Comparison of outcomes after transplantation of peripheral blood stem Cells versus bone marrow following an identical nonmyeloablative conditioning regimen.
- HLA-mismatched renal transplantation without maintenance immunosuppression.
- Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone marrow/kidney transplantation.
- B-Cell immunity in the context of T-Cell tolerance after combined kidney and bone marrow transplantation in humans.
- Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.
- Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.
- Donor-derived interferon gamma is required for inhibition of Acute graft-versus-host disease by interleukin 12.
- Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation.
- My most interesting cases.
- Linezolid-induced lingua villosa nigra.
- Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ''null'' mutation.
- Observation of B[over ¯]→D^{(*)} À^{+}À^{-}ℓ^{-}ν[over ¯] Decays in e^{+}e^{-} Collisions at the ÃŽÂ¥(4S) Resonance.
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Burkitt's Lymphoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
Massachusetts General Hospital -
Semmelweis University
Hospital
-
Massachusetts General Hospital
Drug Facts
| NPI NUMBER | 1679563845 | |
| NPPES Provider LastName | DEY | |
| NPPES Provider FirstName | BIMALANGSHU | |
| NPPES Provider ZIPCode | 021142617 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 476.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 93.0 | |
| Percent Opioid Claims | 19.54 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1679563845 |
| Last Name Of The Provider | DEY |
| First Name Of The Provider | BIMALANGSHU |
| View All |
Similar Doctors
|
|
Dr. Elizabeth A. Guancial, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michal Bar-Natan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cindy Varga, MD |
|
|
Dr. Roberto Mattii, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sol M. Schulman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lidia Schapira, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Stacey M. Gore, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca S. Karp, MD
This Doctor is OpenDoctor Recommended.
|